Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 6/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MYLK | Q15746 | 1/20 | 0.37 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417243 | 0.85 | PTPN5 (0.45) | TMPRSS4P2RX1P2RX4P2RX7MAPT | |
| SCHEMBL4116157 | 0.84 | PTPN5 (0.44) | TMPRSS4P2RX1P2RX4P2RX7MAPT | |
| SCHEMBL3417227 | 0.75 | CNR1 (0.46) | TMPRSS4P2RX1P2RX4P2RX7EGFR | |
| SCHEMBL3420560 | 0.73 | AKR1C2 (0.47) | TMPRSS4P2RX1P2RX4P2RX7PDE2A | |
| SCHEMBL4897243 | 0.70 | CNR2 (0.52) | MAPTPDE2AMEN1KMT2A | |
| SCHEMBL4463291 | 0.69 | P2RX1 (0.39) | TMPRSS4P2RX1P2RX4P2RX7CFTR | |
| SCHEMBL13280707 | 0.68 | CFTR (0.64) | TMPRSS4P2RX1P2RX4P2RX7CFTR | |
| SCHEMBL16148352 | 0.68 | TMPRSS4 (0.63) | TMPRSS4P2RX1P2RX4P2RX7TRPV1 | |
| SCHEMBL28011915 | 0.67 | CA12 (0.64) | TMPRSS4P2RX1P2RX4P2RX7CFTR | |
| SCHEMBL1169878 | 0.67 | EGFR (0.52) | TMPRSS4P2RX1P2RX4P2RX7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | TMPRSS4 791/4885P2RX1 1509/4885P2RX4 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.